NK
NKTX.US Nkarta Inc
- Market cap
- USD 85.2M
- P/E
- -
- P/B
- 0.39x
- ROE
- -62.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NKTX.US undervalued?
Graham numberThe Graham number of Nkarta Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nkarta Inc fundamental analysis
No fundamental analysis for Nkarta Inc yet.
Nkarta Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as …
Full company profileNkarta Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nkarta Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 6.55M | 115K | 385.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.30M | 98.2K | -1.05M | -2.12M | -6.57M | -5.87M | -9.15M | -9.19M | - |
| Operating Income | -356K | -22.3M | -51.5M | -86.4M | -119M | -132M | -128M | -121M | -146M |
| EBITDA | -91.3K | -20.2M | -50.7M | -84.7M | -116M | -120M | -99.6M | -94.9M | -129M |
| Net Income | -275K | -21.1M | -91.4M | -83.9M | -119M | -118M | -109M | -104M | -135M |
| EPS | -0.01 | -2.35 | -2.87 | -2.55 | -2.74 | -2.40 | -1.60 | -1.41 | -1.81 |
| Balance Sheet | |||||||||
| Total Assets | 9.61M | 48.4M | 338M | 274M | 473M | 379M | 501M | 404M | 308M |
| Total Liabilities | 15.0M | 73.9M | 16.4M | 22.9M | 101M | 106M | 93.2M | 91.9M | 92.7M |
| Shareholders' Equity | -5.40M | -25.5M | 321M | 251M | 372M | 273M | 408M | 312M | 216M |
| Cash & Short-term Investments | 7.87M | 37.0M | 315M | 238M | 352M | 248M | 267M | 276M | 157M |
| Total Debt | 12.7M | 7.30M | 8.92M | 12.5M | 82.9M | 88.3M | 80.3M | 76.4M | 72.0M |
| Cash Flow | |||||||||
| Operating Cash Flow | -5.18M | -18.4M | -43.5M | -67.9M | -57.0M | -86.2M | -99.7M | -88.7M | -104M |
| Capital Expenditure | 758K | 1.93M | 7.51M | 5.03M | 47.1M | 28.1M | 4.41M | 1.21M | 2.45M |
| Free Cash Flow | -5.94M | -20.3M | -51.0M | -73.0M | -104M | -114M | -104M | -89.9M | -107M |
| Ratios | |||||||||
| ROE | - | - | -28.4% | -33.5% | -32.1% | -43.0% | -26.7% | -33.3% | -62.7% |
| ROA | -2.9% | -43.5% | -27.1% | -30.6% | -25.3% | -31.0% | -21.7% | -25.8% | -43.9% |
| Net Profit Margin | -4.2% | -18,265.7% | -23,730,129.9% | - | - | - | - | - | - |
| Debt to Equity | - | - | 0.03x | 0.05x | 0.22x | 0.32x | 0.20x | 0.24x | 0.33x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nkarta Inc dividends
Nkarta Inc has not paid dividends in the last 8 fiscal years.
Who owns Nkarta Inc
- Insiders 4.91%
- Institutions 83.09%
- Public & others 12.00%
- Shares outstanding 71.6M
- Free float 60.7M
Top funds holding NKTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.57M | 2.19% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.12M | 1.56% | 0.00% | Oct 2026 |
| Wasatch Micro Cap | 875K | 1.22% | 0.00% | Sep 2026 |
| Wasatch Ultra Growth | 707K | 0.99% | -52.44% | Sep 2026 |
| JPM Thmtcs Gentc Thrps C2 dist USD | 533K | 0.74% | -0.83% | Sep 2026 |
| Fidelity Small Cap Index | 501K | 0.70% | +2.26% | Aug 2026 |
| iShares Russell 2000 Value ETF | 405K | 0.57% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 294K | 0.41% | -0.38% | Sep 2026 |
| BlackRock Advantage Small Cap Gr Instl | 270K | 0.38% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 259K | 0.36% | +0.99% | Sep 2026 |
| Dimensional US Small Cap ETF | 151K | 0.21% | 0.00% | Oct 2026 |
| iShares Micro-Cap ETF | 136K | 0.19% | 0.00% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 131K | 0.18% | +225.67% | Sep 2026 |
| Schwab Small Cap Index | 108K | 0.15% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 107K | 0.15% | 0.00% | Oct 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 100K | 0.14% | 0.00% | Oct 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 94.2K | 0.13% | -5.89% | Oct 2026 |
| Avantis US Small Cap Equity ETF | 90.3K | 0.13% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 86.9K | 0.12% | -0.05% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 86.2K | 0.12% | 0.00% | Sep 2026 |
Top institutions holding NKTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 10.8M | 15.09% | 0.00% | Jun 2026 |
| BlackRock Inc | 6.30M | 8.80% | +39.74% | Jun 2026 |
| NEA Management Company, LLC | 3.57M | 4.98% | 0.00% | Jun 2026 |
| Samsara BioCapital, LLC | 3.51M | 4.90% | 0.00% | Jun 2026 |
| SR ONE CAPITAL MANAGEMENT, LP | 3.33M | 4.65% | 0.00% | Jun 2026 |
| GSK PLC | 3.15M | 4.40% | 0.00% | Jun 2026 |
| Monaco Asset Management | 2.37M | 3.31% | -5.89% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.23M | 3.11% | +10.69% | Jun 2026 |
| Citadel Advisors Llc | 2.17M | 3.04% | +21.90% | Jun 2026 |
| Two Sigma Investments LLC | 1.87M | 2.62% | -8.50% | Jun 2026 |
| Acadian Asset Management LLC | 1.73M | 2.41% | +27.06% | Sep 2026 |
| Wasatch Advisors LP | 1.58M | 2.20% | 0.00% | Jun 2026 |
| State Street Corp | 1.29M | 1.80% | +3.93% | Jun 2026 |
| Geode Capital Management, LLC | 1.29M | 1.79% | +1.39% | Jun 2026 |
| AQR Capital Management LLC | 1.05M | 1.47% | +76.97% | Jun 2026 |
| Awm Investment Company Inc | 906K | 1.26% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 799K | 1.12% | -32.13% | Sep 2026 |
| Blackstone Inc | 747K | 1.04% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 673K | 0.94% | 0.00% | Jun 2026 |
| Panagora Asset Management Inc | 583K | 0.81% | +105.22% | Jun 2026 |
Nkarta Inc company profile
- Company name
- Nkarta Inc
- Ticker
- NKTX.US
- Exchange
- USA Stocks
- Listed since
- Jul 10, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 103
- Fiscal year end
- December
- Address
- 1150 Veterans Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 925 407 1049
- Website
- nkartatx.com
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Nkarta Inc management
3- Mr. Paul J. HastingsCEO & Director · born 1960
- Dr. Nadir Mahmood Ph.D.President and Principal Accounting & Financial Officer · born 1980
- Dr. Shawn Rose M.D., Ph.D.Chief Medical Officer and Head of Research & Development